KDventures: Umecrine’s Power Sufficient - Redeye

Redeye comments on the interim analysis of the phase Ib/IIa study of golexanolone in primary biliary cholangitis with cognitive fatigue. The analysis concludes that patient recruitment can continue as planned with no increase in the pre-defined study size.

Länk till analysen i sin helhet: https://www.redeye.se/research/1172706/kdventures-umecrines-power-sufficient?utm_source=finwire&utm_medium=RSS